What did Semaglutide change in the people studied?
Large trials measured weight loss and a lower combined risk of serious heart or kidney trouble in selected patients. Your illnesses and the harms of treatment still affect the choice of care.
Which study results matter most for your choices?
Large trials measured substantial weight loss and fewer serious problems involving the heart or kidneys. The benefits were measured in groups with the illnesses described below. Your benefit can't be forecast simply by taking an average from those patients. Stomach trouble and other risks belong in the same discussion as the gains.
Researchers also studied changes in hunger-control brain areas, mainly through animal tests. Those tests help explain why eating might fall, while human studies measure weight and health changes. You can judge a benefit more clearly when you know who was actually studied. Read the effects page alongside these findings to weigh what could make treatment harder.
Why can both eating and sugar readings fall?
Semaglutide acts like GLP-1, the gut hormone that prompts a response when food arrives. The pancreas, a gland behind your stomach, releases more insulin when sugar has risen. Insulin helps lower blood sugar, so extra release can improve your sugar readings. The medicine also curbs excess glucagon, the hormone that prompts the body to put more sugar into blood, while slower stomach emptying steadies the rise after meals [5].
Tests in mice and rats found less eating when semaglutide reached areas controlling appetite [4]. The animals chose different foods, but their bodies didn't start using less energy at rest. Their weight fell mainly because they ate less, without having to burn food faster. Animal tests explain a possible cause, without measuring your appetite.
Some brain cells encourage eating, while others help the animal finish a meal. Drugs acting like GLP-1 shifted brain-cell activity toward curbing eating during animal tests [8]. The response depended on time after drug exposure and whether the animal was hungry. Earlier mouse work also found that blocking action in that brain area prevented the drug group's weight loss [9].
How far did weight fall in the Semaglutide STEP studies?
STEP 1 followed 1,961 overweight adults without diabetes for 68 weeks [1]. Weekly semaglutide 2.4 mg gave average weight change of -14.9%; placebo, treatment without active drug, gave -2.4%. The difference was 12.4 percent of starting weight, found by subtracting the smaller loss. STEP 2 also found substantial loss in adults with type 2 diabetes [10].
Your weight won't necessarily fall by the average amount reported for either group. Overweight adults also had improved blood tests, a fall in blood pressure and smaller waists [14]. Those blood tests covered sugar, fats and signs of inflammation, but improvements chiefly lasted while treatment continued. The effects page explains why weight returning after stopping matters when you weigh long-term care.
How should you read the heart and kidney risk figures?
SELECT included 17,604 adults with obesity and existing heart disease, without diabetes. With semaglutide 2.4 mg, combined risk of stroke, heart attack or death related to the heart fell by 20% [3]. That means the combined risk was a fifth lower than the comparison group's risk. The percentage alone can't count patients spared trouble or predict your benefit.
SUSTAIN-6 studied 3,297 high-risk adults with type 2 diabetes, using weekly 0.5 or 1.0 mg [2]. Serious heart and stroke problems fell, but problems from diabetic eye disease increased. The eye trouble was especially marked among patients whose eyes had damage before treatment. Your doctor needs to weigh that harm alongside the lower heart risk.
FLOW followed 3,533 patients with type 2 diabetes and long-standing kidney disease [6]. With semaglutide 1.0 mg, the combined risk fell by 24% compared with the other group. Kidney failure, major loss of blood filtering and deaths from kidney or heart problems were counted together. That figure concerns the combined count; it doesn't mean every kind of problem fell equally.
Which lost more weight: Semaglutide or tirzepatide?
Doctors use tirzepatide, a different medicine, to treat diabetes and help with weight control. SURMOUNT-5 followed 751 adults with obesity for 72 weeks, comparing that drug with semaglutide [7]. Average weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The gap was roughly 6.5 percent of starting weight and was unlikely to reflect chance alone.
Tirzepatide acts like GIP, a hormone from the gut that prompts insulin release, and GLP-1, which helps bring fullness. Semaglutide follows GLP-1 alone, and has more large studies of the kidneys and heart, including SELECT and FLOW. Tirzepatide gave more weight loss in this trial, while leaving other health benefits to weigh. Your illnesses and side effects affect the choice between these medicines.
What changed with Semaglutide tablets and other diabetes drugs?
Combining the tablet studies in a review showed improvements in sugar readings and lower weight [11]. The blood test measured average sugar over three months, rather than one reading. Heart findings broadly agreed with those for other GLP-1 medicines in type 2 diabetes. That doesn't mean the tablet and shot will suit your health equally well.
PIONEER PLUS compared 25 mg and 50 mg tablets with 14 mg in diabetes [13]. Participants' sugar stayed above target despite treatment; that isn't a judgment about their effort. Higher amounts of this GLP-1 medicine gave larger falls in sugar and weight than the smaller amount did. SUSTAIN 7 found larger falls with semaglutide than dulaglutide, another shot for treating diabetes [12].
A 2024 review brought together findings on appetite, sugar and other effects in the body [15]. Much of the detailed explanation came from tests using mice and rats, rather than human brains. Human trials tell you what changed in people; animal tests help explain possible causes. The comparisons describe research, so your doctor needs your health history to choose treatment.